GSK Seeks Re-Entry To Parkinson's Market In Deal With Impax
This article was originally published in The Pink Sheet Daily
Executive Summary
With no Parkinson's candidates in its pipeline, the pharma pays $11.5 million upfront for ex-U.S. rights to Phase III compound.
You may also be interested in...
Impax/GSK's Extended-Release Parkinson's Treatment IPX066 Aces Third Phase III Trial
Impax plans Q4 FDA submission, while GSK will approach European regulators in 2012.
Impax/GSK's Extended-Release Parkinson's Treatment IPX066 Aces Third Phase III Trial
Impax plans Q4 FDA submission, while GSK will approach European regulators in 2012.
Impax Transferring Products To Taiwan After GMP Warning Letter For U.S. Plant
Impax Laboratories says it has been transferring important products from a Hayward, Calif. manufacturing facility targeted by a U.S. FDA warning letter to a new facility in Taiwan as it works to resolve regulatory issues in the U.S. plant and prepare for a re-inspection